Professional
Added to YB: 2024-10-31
Pitch date: 2024-09-30
NTRA [bullish]
Natera, Inc.
+82.97%
current return
Author Info
No bio for this author
Company Info
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Market Cap
$28.2B
Pitch Price
$126.77
Price Target
N/A
Dividend
N/A
EV/EBITDA
-91.38
P/E
-89.19
EV/Sales
12.92
Sector
Biotechnology
Category
growth
Artisan Global Equity Fund Portfolio Holding: Natera, Inc.
NTRA: Genetic tester Natera's Signatera™ blood test shows improved survival in colorectal cancer. Likely to become standard of care, risking liability for non-use. Near-term catalysts in other areas. $15B market opportunity. Strong returns in healthcare sector.
Read full article (1 min)